BioCentury | Sep 8, 2008
Company News

Eagle Pharmaceuticals Pty., OncoGenex Technologies deal

...Eagle received exclusive, worldwide rights to OncoGenex’s Tocosol paclitaxel. OncoGenex is eligible for undisclosed royalties and...
...received by Eagle. OncoGenex gained the paclitaxel product that is formulated with the vitamin E-based Tocosol...
BioCentury | Jun 2, 2008
Finance

Ebb & Flow

...explore strategic options. The prior month, the biotech and partner Bayer (Xetra:BAY) stopped development of Tocosol...
BioCentury | Oct 29, 2007
Finance

Ebb & Flow

...its strategic options. In late September, SNUS and partner Bayer (FSE:BAY; BAY) stopped development of Tocosol...
...Oct. 1). SNUS expects Phase I data by year end for its second oncology candidate, Tocosol...
BioCentury | Oct 1, 2007
Analyst Picks & Changes

Analyst picks & changes

...Chris Holterhoff Downgrade Source of funds (from buy) Kaplan removed his $10 target after SNUS's Tocosol...
...E-based Tocosol drug delivery system. Holterhoff lowered his target to $0.60 from $10 on the Tocosol...
BioCentury | Oct 1, 2007
Finance

3Q approvals

...efficacy data when compared to reference drugs were not sufficient for approval. Sonus (SNUS) IV Tocosol...
BioCentury | Oct 1, 2007
Finance

Ebb & Flow

...see B20). Sonus (SNUS) dropped $3.65 (84%) to $0.70 on Monday after the company's IV Tocosol...
...metastatic breast cancer. SNUS and partner Bayer (FSE:BAY; BAY) are closing all clinical trials of Tocosol...
BioCentury | Oct 1, 2007
Clinical News

Tocosol paclitaxel: Phase III data

...the open-label, international Phase III SON-8184-1075 trial in 821 women with metastatic breast cancer, IV Tocosol...
...closing all clinical trials of Tocosol. SNUS also said it expects BAY to terminate the Tocosol...
...Germany Product: Tocosol paclitaxel Business: Cancer Molecular target: Tubulin Description: Paclitaxel formulated with vitamin E-based Tocosol...
BioCentury | Sep 25, 2007
Clinical News

Sonus falls after Tocosol miss

...SNUS dropped $3.65 (84%) to $0.70 on 37.3 million shares on Monday after IV Tocosol paclitaxel...
...In the open-label, international study in 821 women, the objective response rate was 37% for Tocosol...
...submission, and the company and partner Bayer (FSE:BAY; BAY) are closing all clinical trials of Tocosol...
BioCentury | Jul 2, 2007
Finance

2H milestones

...response YE07 SkyePharma (LSE:SKP; SKYE)/Mundipharma/Abbott (ABT) Flutiform Asthma Submit NDA YE07 Sonus (SNUS)/Bayer (FSE:BAY; BAY) Tocosol...
BioCentury | Apr 2, 2007
Finance

2Q Financial Markets Preview: Three legs to stand on

...Wash.) interesting: the cancer company expects to report Phase III data this summer for its Tocosol...
Items per page:
1 - 10 of 66